Non-Melanoma Skin Cancers

Topical microtubule inhibitor, tirbanibulin (Klisyri, Almirall), demonstrates positive results for treating actinic keratosis (AK) of the face and scalp, according recently published data from two phase 3 studies.

The FDA has approved cemiplimab-rwlc as the first immunotherapy for use in patients with advanced basal cell carcinoma that has previously been treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate.

A recent study found states' Medicare per-beneficiary spending between actinic keratosis and skin cancer differs widely.

While Mohs micrographic surgery is well established as a safe and effective therapeutic modality in adult patients, it is not as commonly used in pediatric populations. There are unique challenges to performing Mohs surgery on pediatric patients, especially with patient cooperation. Multidisciplinary planning may be needed.

Investigators of a recent study found a 40-gene expression profile (40-GEP) test helps improve identification of high risk for metastatic disease in patients with cutaneous squamous cell carcinoma (cSCC).

Superficial radiation offers a newer, FDA-approved office-based option that is safe. Steven A. Davis, M.D., shares his experience using surface radiotherapy to treat his patients with non-melanoma skin cancer.

Promising outcomes are being reported from clinical trials investigating Nano-Pulse Stimulation technology to treat nodular basal cell carcinoma and cutaneous, non-genital warts.

Michelle Nguyen, M.D., MPH, sits down with Dermatology Times to discuss her recent presentation at the 2020 American Society for Dermatologic Surgery (ASDS) virtual meeting regarding the representation of women dermatologic surgeons in the U.S.

A recent study showed that curettage and cryotherapy, and electrodesiccation and curettage are two techniques that have comparable cure rates. The study’s findings highlight the efficacy and reliability of these treatment approaches for minimally invasive cutaneous carcinomas.

A recent study underscores the need for a consistent scale to grade risk levels of cutaneous squamous cell carcinoma (SCC), particularly poorly differentiated tumors, according to study authors who presented at the 2020 virtual American Society for Dermatologic Surgery (ASDS) meeting.

A recent survey shows that many consumers are confused about sunscreen labeling claims regarding sun protection factor (SPF), allergenicity and other features.

Cutaneous squamous cell carcinoma (cSCC) patients need close clinical follow-up after being diagnosed with the skin cancer because subsequent cSCC development is likely in the following months and years.

A recent study from the University of Missouri School of Medicine investigates when is the best time to make post-operative phone calls to patients following Mohs micrographic surgeries.

Castle Biosciences announces the launch of DecisionDx-SCC, a prognostic gene expression profile test for patients with high-risk cutaneous squamous cell carcinoma (cSCC).

The International Skin Imaging Collaboration is an academic and industry partnership designed to facilitate the clinical application of digital skin imaging, with an initial focus on melanoma. The group is developing standards for dermatologic imaging and building a public archive of clinical and dermoscopic images for use in developing artificial intelligence diagnostic algorithms.

Findings from a survey of college students examining beliefs about UV exposure and sunscreen use and their associations with skin cancer risk and UV protective behaviors provide some insights for patient counseling.

Findings of initial studies and call for further testing should not be misconstrued to mean ingredients are unsafe.

Treatment for Merkel cell carcinoma has evolved due to the high aggressiveness and metastatic rate of the tumors. Immune checkpoint inhibitor therapy may change prognosis and quality of life.

The biology of nonmelanoma skin cancers and their strong immunogenicity makes these tumors good candidates for novel and emerging immunotherapeutic agents.

The U.S. Food and Drug Administration has approved pembrolizumab for cutaneous squamous cell carcinoma whose disease has shown to not be curable by radiation or surgery.

In case you missed it, this week we featured stories involving blastic plasmacytoid dendritic cell neoplasm (BPDCN), development of a biosimilar to BOTOX, a new nonmelanoma treatment device, the latest phase 3 results for abrocitinib in atopic dermatitis, results from a long-term dabrafenib and trametinib study in stage 3 BRAF-mutated melanoma, plus many more.

A new systemic medication option offers promising results for patients with high-risk squamous cell carcinoma for whom surgery has not worked, says this expert.

Fruits and vegetables rich in vitamin A appear to play a significant role in helping to decrease the incidental risk of developing squamous cell carcinoma, according to a recent study.

New German basal cell carcinoma (BCC) guidelines are more alike than unlike U.S. guidelines, although minor differences exist in areas such as prevention and newer systemic treatments, says experts.

Researchers recently examined a non-invasive test that, if additional studies can confirm, may directly affect future patient care for patients at risk for non-melanoma skin cancer.